On May 13, 2019, the U.S. Food and Drug Administration (FDA) expanded the approved use of eye drug Eylea (aflibercept) to include treatment of all stages of diabetic retinopathy. More than 5.3 million adults in the United States are estimated to have diabetic retinopathy, which occurs when diabetes damages tiny blood vessels in the eye’s retina (the light-sensitive tissue at the back of the eye).
Eylea, which is also approved to treat wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy in people who have diabetic macular edema is administered via injection into the eye — monthly for the first five months and then once every other month — by a health-care professional.
The approval was based on the results of the phase 3 PANORAMA trial, which evaluated the effect of Eylea on moderately severe to severe non-proliferative diabetic retinopathy compared to a sham (inactive) injection in 402 participants.
For more information about Eylea, see the press release on the Regeneron website.
Want to learn more about keeping your eyes healthy with diabetes? Read “Eating for Better Vision and Healthy Eyes” and “Keeping Your Eyes Healthy” and watch “Diabetes and Your Eyes.”
Source URL: https://www.diabetesselfmanagement.com/blog/new-medicine-diabetic-retinopathy/
Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)
Disclaimer of Medical Advice: Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information, which comes from qualified medical writers, does not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs.
Copyright ©2022 Diabetes Self-Management unless otherwise noted.